CA3041066A1 - Nanocorps anti-tau - Google Patents

Nanocorps anti-tau Download PDF

Info

Publication number
CA3041066A1
CA3041066A1 CA3041066A CA3041066A CA3041066A1 CA 3041066 A1 CA3041066 A1 CA 3041066A1 CA 3041066 A CA3041066 A CA 3041066A CA 3041066 A CA3041066 A CA 3041066A CA 3041066 A1 CA3041066 A1 CA 3041066A1
Authority
CA
Canada
Prior art keywords
seq
tau
nanobodies
nanobody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3041066A
Other languages
English (en)
French (fr)
Inventor
Daniel Fagret
Marcelle MOULIN
Catherine Ghezzi
Pascale Perret
Sabine CHIERICI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Grenoble
Universite Grenoble Alpes
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Grenoble
Universite Grenoble Alpes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Grenoble, Universite Grenoble Alpes filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of CA3041066A1 publication Critical patent/CA3041066A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3041066A 2016-10-27 2017-10-27 Nanocorps anti-tau Pending CA3041066A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1660450 2016-10-27
FR1660450A FR3058143B1 (fr) 2016-10-27 2016-10-27 Nanocorps anti-tau
PCT/EP2017/077691 WO2018078140A1 (fr) 2016-10-27 2017-10-27 Nanocorps anti-tau

Publications (1)

Publication Number Publication Date
CA3041066A1 true CA3041066A1 (fr) 2018-05-03

Family

ID=58314353

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3041066A Pending CA3041066A1 (fr) 2016-10-27 2017-10-27 Nanocorps anti-tau

Country Status (7)

Country Link
US (1) US10590191B2 (https=)
EP (1) EP3532495A1 (https=)
JP (1) JP7197494B2 (https=)
CN (1) CN110225926B (https=)
CA (1) CA3041066A1 (https=)
FR (1) FR3058143B1 (https=)
WO (1) WO2018078140A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019017021A2 (pt) 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
CN112649615A (zh) * 2020-12-21 2021-04-13 大连理工大学 一种检测不同大小的可溶性Aβ寡聚体的方法及应用
FR3134390B1 (fr) 2022-04-11 2025-10-24 Univ Grenoble Alpes Peptide utile pour le transport de molecules au travers de barrieres cellulaires

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
MX9701720A (es) 1994-09-12 1997-06-28 Schering Ag Proceso para la fabricacion de una palidipina modificada, inhibidora de la agregacion plaquetaria inducida por colageno.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP2470211B1 (en) * 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
WO2014059442A2 (en) * 2012-10-12 2014-04-17 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
ES2800827T3 (es) * 2013-06-10 2021-01-04 Ipierian Inc Procedimientos de tratamiento de una tauopatía
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof

Also Published As

Publication number Publication date
JP2020505056A (ja) 2020-02-20
WO2018078140A1 (fr) 2018-05-03
EP3532495A1 (fr) 2019-09-04
CN110225926B (zh) 2024-05-03
FR3058143B1 (fr) 2021-03-12
FR3058143A1 (fr) 2018-05-04
US20190263898A1 (en) 2019-08-29
CN110225926A (zh) 2019-09-10
US10590191B2 (en) 2020-03-17
JP7197494B2 (ja) 2022-12-27

Similar Documents

Publication Publication Date Title
EP3160999B1 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
JP6345655B2 (ja) タウに対する抗体
RU2555526C2 (ru) Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий
EP2576617B1 (en) MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS
US11028157B2 (en) Binding molecules that specifically bind to tau
CN101883792B (zh) 特异于β-淀粉状蛋白肽的新抗体以及其用作诊断剂或药物的用途
CA2846251C (fr) Nanocorps anti-vcam-1
HUE031944T2 (en) Antibodies capable of specific binding of amyloid β-oligomers and their use
GB2507207A (en) Treatment of Tauopathies
HUE027649T2 (en) Antibodies recognising phospho-tau
US20200369754A1 (en) Binding molecules that specifically bind to tau
JP2023521763A (ja) 抗ｐｈｆ－タウ抗体及びその使用
CA3041066A1 (fr) Nanocorps anti-tau
CN118369329A (zh) 治疗神经退行性疾病的方法和物质
US11274147B2 (en) Binding molecules that specifically bind to tau
EA047298B1 (ru) Антитела к phf-тау и их применение

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220728

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240927

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241007

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241007

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241007

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250116

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250214

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250627

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250627

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251014

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251014

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128